The OncoAlert 🚨 Network is Proud to be collaborating with our friends at Advanced Prostate Cancer Consensus Conference

#APCCC24 NEXT WEEK: April 25-27, 2024
Register Here onlineevent.ch/APCCC/2024
ONLINE REGISTRATION FREE FOR SOME LMIC's

Follow Our Ambassadors for coverage of this Great event in…

Perspective from phase II experience High risk local prostate cancer enriched for aggressive phenotype more than all comer mHSPC . BUT a subset benefit from 6 m neoadj adt asi sparing a 2yr exposure +ebrt . Those with ypT2N0 ‘cured’-baseline predictors key. PROTEUS data coming

The OncoAlert 🚨 Network is Proud to announce our collaboration with our friends at Advanced Prostate Cancer Consensus Conference
and will be covering #APCCC24 LIVE April 25-27, 2024

Register Here onlineevent.ch/APCCC/2024

Follow Our Ambassadors for coverage of this Great event in #ProstateCancer

The…

Transformative and as hoped positive trial 🙏🏼 great news for advanced urothelial cancer treatment with EV Pembro .. next stop neoadjuvant !

#weareTexans
Texans Ready to Swarm !!! Early In place and Ready to be loud !! 🫡 let’s Go !!! #texansplayoffs

The latest #ESMOGuidelines webinar on #ProstateCancer now available on-demand. Access the resources with your free ESMO account and learn how these recommendations can assist in your daily practice. Available here: ow.ly/pLWE50QeWS8
Eleni Efstathiou Matthieu Delaye #PCSM

Last call 📢 Register today for a unique opportunity to submit your questions to experts in #ProstateCancer developing and implementing the ESMO Guidelines.
⏰ 28 Nov at 18:30 CET.
Register now: ow.ly/Nur950QbRbT

Eleni Efstathiou Matthieu Delaye #PCSM

Learn about the role of approved & emerging therapies in #ProstateCancer care plans that incorporate new data & guideline recommendations. Join Drs. Shore, Smith, Ashley Ross MD PhD & Eleni Efstathiou on 12/1 at 11:30 AM EST at #SUO23 ! bit.ly/Prostate23T ZERO Prostate Cancer

🚀 Elevate the Consenus at #APCCC 24 !

🌟 Engage, Debate, Shape Future Guidelines!

🔗 Meet the Panel & Join Us → bit.ly/46i3Hao

#ProstateCancer #Oncology #CancerResearch #MedicalConference #ClinicalConsensus #APCCC

An absolute honor to be a part of the 20th BUG meeting ! Indebted to Heather Payne for her guidance wisdom perseverance camaraderie and I m so proud to say her friendship ! Thank you for leading always by example 🙏🏼 #prostatecancer Houston Methodist

Perseverance and Precision make Progress 💪🏼

Dr Niravath is one of those magical and rare speakers who makes even the most complex notions understood 🙏🏼 and so exciting ! Breast Cancer Research Crown Jewel Houston Methodist MD Jenny C. Chang Houston Methodist

A phenomenal Tour de Force by the Trailblazer Dr Hussain 🙏🏼

So honored to be a part of our Neal Cancer Center Symposium Houston Methodist MD Houston Methodist

So Honored to have one of the Giants of GU oncology Dr Maha Hussain as one of our keynote speakers during our Houston Methodist Cancer Symposium 🙏🏼Houston Methodist Houston Methodist MD

Love it when we have to summarize all my take home messages in few secs . Puts everything in perspective when you compare notes

En route to #CUA23 🇨🇦 🤩! So very Honored to give the state of the art lecture on the advances we ve made in metastatic prostate cancer therapy and to top it off in a country that s so very close to my heart🍁 🇨🇦 🙏🏼Houston Methodist MD

This is what hit the ground running looks like !! 🤩

Great Win for precision medicine in #prostatecancer #ASCO23 ! Tonight join us Neeraj Agarwal, MD, FASCO Atish Choudhury, MD PhD and #EvanYu for a PER ‘hot seat ‘ symposium on parp inhibition in mCRPC ! Promise to make it a ‘true ‘ hot seat for our faculty ! bit.ly/3B6i1od

Talapro -2 DDR cohort subset data : HR 0.19 for BRCA2 !! Interesting cdk12 positive outcomes. Reproducibility in 3 studies combining parp with AR inhibition . Let s continue honing into precision . Neeraj Agarwal, MD, FASCO Elena Castro OncoAlert high5md Petros Grivas #ASCO2023